Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal annamycin plus cytarabine in acute myeloid leukemia
2024-516388-10-00Phase 2Completed
- Sponsor
- Moleculin Biotech, Inc.
- Start
- Aug 2024
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of annamycin and liposomal cytarabine in acute myeloid leukemia (AML), sponsored by Moleculin Biotech, Inc. Primary endpoints: Complete remission, Complete remission with incomplete count recovery and 2 more. Started Aug 2024; status: completed.
02
Drugs
annamycinliposomal cytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-516388-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516388-10-00.